INTRODUCTION {#s1}
============

Morbidity and mortality of colorectal cancer is steadily increasing, which severely threatens human health. This tumor is the third cause of death from all malignancies \[[@R1]\]. In the past 30 years, therapies for rectal cancer have gained great improvements. Indeed, total mesorectal excision (TME) and neoadjuvant chemoradiotherapy (nCRT) greatly decrease local relapse rate and increase patient survival, and are considered standard therapies for locally advanced rectal cancer (LARC) \[[@R2]--[@R4]\]. However, markedly different therapeutic effects are obtained for various nCRT modalities; some cases can achieve pathological complete response (pCR), while others are not sensitive or even resistant. Therefore, sensitivity genes should be urgently identified to predict the effect of nCRT on rectal cancer. This would allow accurate individualized therapy.

GOLPH3 (Golgi phosphoprotein 3) belongs to the first class of Golgi proteins \[[@R5]\]. It is a highly preserved protein and an effector for phosphatidylinositol-4-monophosphate (PI4P) in the Golgi apparatus \[[@R6]\]. It is demonstrated that GOLPH3 plays a very important role in regulating cell division, mitochondrial mass, and DNA damage \[[@R7]--[@R10]\]. Furthermore, GOLPH3 activates the mTOR (mammalian target of rapamycin) pathway, Scott et al. reported \[[@R11]\], which is critical in the regulation of cell proliferation, growth and activity \[[@R12]\]. Recent studies indicated that GOLPH3 was highly expressed in malignant tumors, including colorectal, breast, renal, pancreatic, and non-small cell lung cancers, and closely associated with clinical staging and poor prognosis of the tumor \[[@R13]--[@R17]\].

Two reports assessing GOLPH3 in rectal cancer have been published. Guo et al. showed that GOLPH3 was highly expressed in rectal cancer (53.2%), significantly higher than the value obtained for the normal tissue (24.2%). In addition, patients with high GOLPH3 expression had poorer prognosis \[[@R13]\]. Wang et al. demonstrated that GOLPH3 was highly expressed in colorectal cancer (43.1%), higher than in the surrounding normal tissue (13.3%) \[[@R18]\]. Furthermore, GOLPH3 overexpression was shown to promote the apoptotic effect of 5-Fu. Taken together, findings suggested that GOLPH3 could be used as an important indicator for predicting sensitivity to 5-Fu \[[@R18]\]. However, there is no report available to assess the relationship between GOLPH3 and efficacy of nCRT for rectal cancer.

The aim of this study was to assess GOLPH3 expression in rectal cancer, and determine its associations with clinical pathological characteristics and prognosis, evaluating its value as a potential independent predictive indicator for nCRT sensitivity and prognosis. Meanwhile, mTOR expression was quantitated to explore the underlying mechanism.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The clinical pathological characteristics of the 148 LARC patients are listed in Table [1](#T1){ref-type="table"}. There were 89 (60.14%) males and 59 (39.86%) females, with 81 (54.73%) patients above 65 year-old and 67 (45.27%) below 65. Average patient age was 63.2 years. The lump was located at 6 cm within the anal verge in 57 (38.51%) cases, and beyond 6 cm in the remaining 91 (61.49%) patients. Postoperative pathological results indicated 82 (55.41%) cases with high tumor tissue differentiation, and 66 (44.59%) with low differentiation. Among the 148 cases, 80 (54.05%) and 68 (45.95%) had cT3 and cT4 disease stages, respectively; 54 (36.49%) cases were in cN0 stage, and 94 (63.51%) in cN+ stage.

###### Correlations between GOLPH3 expression and clinicopathological parameters

  Clinicopathological parameters   Cases (*n* = 148)   GOLPH3 expression   *P* value   
  -------------------------------- ------------------- ------------------- ----------- -------
  Gender                                                                               
   Male                            89                  41                  48          0.569
   Female                          59                  30                  29          
  Age (years)                                                                          
   \< 65                           67                  35                  32          0.345
   ≥ 65                            81                  36                  45          
  Histology                                                                            
   Differentiated                  82                  47                  35          0.011
   Undifferentiated                66                  24                  42          
  Distance from anal verge(cm)                                                         
   \< 6                            57                  29                  28          0.576
   ≥ 6                             91                  42                  49          
  CEA(ng/ml)                                                                           
   \< 3.4                          70                  41                  29          0.014
   ≥ 3.4                           78                  30                  48          
  Clinical Tumor status                                                                
   cT3                             80                  45                  35          0.029
   cT4                             68                  26                  42          
  Clinical Node status                                                                 
   cN0                             54                  32                  22          0.037
   cN+                             94                  39                  55          
  Recurrence                                                                           
   Negative                        105                 59                  46          0.002
   Positive                        43                  12                  31          
  Distant metastasis                                                                   
   Negative                        122                 64                  58          0.018
   Positive                        26                  7                   19          

Abbreviations: GOLPH3, Golgi phosphoprotein 3; CEA, carcinoembryonic antigen.

Expression of GOLPH3 in tumor and normal tissues and its associations with clinicopathological parameters of LARC {#s2_2}
-----------------------------------------------------------------------------------------------------------------

The associations of GOLPH3 expression and LARC clinical pathological characteristics are shown in Table [1](#T1){ref-type="table"}. GOLPH3 was highly expressed in rectal cancer cell cytoplasm, with 77 (52.03%) cases showing high expression. However, low expression was found in normal surrounding rectum tissues, with only 11 of 87 (12.64%) cases showing high expression. The difference was statistically significant (*P* \< 0.001) (Figure [1](#F1){ref-type="fig"}). In addition, high GOLPH3 expression was associated with tumor differentiation (*P* = 0.011), increased serum CEA (*P* = 0.014), tumor invasion depth (T staging) (*P* = 0.029) and lymphatic metastasis (*P* = 0.037), but not with gender, age and tumor location. Among the 77 patients with high GOLPH3 expression, 31 cases had local relapse, while 19 patients showed distant metastasis. Of the 71 patients with low expression, 12 and 7 cases had local relapse and distant metastasis, respectively. These findings indicated significant differences in local relapse (*P* = 0.002) and distant metastasis (*P* = 0.018) rates between the two groups.

![Expression of GOLPH3 in rectal tissues\
Immunohistochemical staining for GOLPH3 in rectal cancer cells cytoplasm (T: Tumor, High) and matched normal tissues (N: Normal, Low), magnification is 400×.](oncotarget-07-68328-g001){#F1}

Correlation between GOLPH3 expression and tumor response {#s2_3}
--------------------------------------------------------

According to the AJCC (Edition 7) standard, preoperative and postoperative pathological staging was performed to analyze the down-staging effect of nCRT. A total of 77 cases showed tumor down-staging among the 148 cases (52.03%). Meanwhile, TRG was used to assess the therapeutic effect of nCRT. There were 69 cases (46.62%) with TRG 3--4 (sensitivity to nCRT) and 79 (53.38%) with TRG 0--2 (non-sensitivity). Interestingly, low GOLPH3 expression tended to yield high sensitivity to nCRT: among the 71 patients with low expression, 44 cases showed tumor down-staging; meanwhile, 33 of the 77 cases with high expression showed down-staging (*P* = 0.020). And of the 71 low expression cases 41 showed TRG 3--4, with 28 such patients found among the 77 cases with high expression (*P* = 0.009). Besides, tumor down-staging and TRG 3--4 in patients with low CEA level and no lymph node metastasis were higher compared with values found in those with high CEA level and lymph node metastasis (*P* = 0.001 and 0.001; *P* = 0.001 and *P* = 0.001, respectively). As for tumor invasion depth, sensitivity to radiotherapy in cT3 stage patients was higher than in cT4 cases. *P* values for tumor down-staging and TRG were 0.035 and *P* = 0.027, respectively (Table [2](#T2){ref-type="table"}).

###### Correlations between clinicopathological parameters and tumor response in LARC

  Parameters                 Cases *n* = 148   TRG   *P* value   Tumor staging   *P* value        
  -------------------------- ----------------- ----- ----------- --------------- ----------- ---- -------
  Age(years)                                                                                      
   \< 65                     67                33    34          0.559           35          32   0.963
   ≥ 65                      81                36    45                          42          39   
  Sex                                                                                             
   Male                      89                43    46          0.612           50          39   0.214
   Female                    59                26    33                          27          32   
  Distance from anal verge                                                                        
   \< 6 cm                   57                27    30          0.885           32          25   0.428
   ≥ 6 cm                    91                42    49                          45          46   
  Histology                                                                                       
   Differentiated            82                37    45          0.684           40          42   0.378
   Undifferentiated          66                32    34                          37          29   
  CEA(ng/ml)                                                                                      
   \< 3.4                    70                45    25          0.001           49          21   0.001
   ≥ 3.4                     78                24    54                          28          50   
  Clinical Tumor status                                                                           
   cT3                       80                44    36          0.027           48          32   0.035
   cT4                       68                25    43                          29          39   
  Clinical Node status                                                                            
   cN0                       54                39    15          0.001           40          14   0.001
   cN+                       94                30    64                          37          57   
  GOLPH3                                                                                          
   Low                       71                41    30          0.009           44          27   0.020
   High                      77                28    49                          33          44   

Abbreviations: LARC, locally advanced rectal cancer; TRG, tumor regression grade ; CEA, carcinoembryonic antigen ; GOLPH3, Golgi phosphoprotein 3.

By multi-factor correlation regression analysis, it was found that low GOLPH3 expression was significantly associated with TRG (OR = 3.952; CI 1.655--10.327, *P* = 0.026) and tumor down-staging (OR = 2.951; CI 1.523--11.324, *P* = 0.021), suggesting GOLPH3 could independently predict sensitivity to nCRT in rectal cancer, with high sensitivity in the low expression group. Besides, tumor invasion depth and lymph node metastasis status also showed significant associations with TRG and tumor down-staging (0.039 and 0.034; 0.029 and 0.037, respectively) (Table [3](#T3){ref-type="table"}).

###### Multivariate analysis for tumor response of nCRT in LARC

  Parameters      Odds ratio   95% Confidence interval   *P* value
  --------------- ------------ ------------------------- -----------
  Good response                                          
   CEA            1.871        0.834--3.981              0.182
   cT             2.762        1.112--6.356              0.039
   cN             2.654        1.136--6.524              0.034
   GOLPH3         3.952        1.655--10.327             0.026
  Down staging                                           
   CEA            1.961        0.864--4.125              0.352
   cT             2.638        1.109--6.356              0.029
   cN             2.456        1.694--5.324              0.037
   GOLPH3         2.951        1.523--11.324             0.021

Abbreviations: nCRT, neoadjuvant chemoradiotherapy; LARC, locally advanced rectal cancer ; cT, clinical Tumor status; cN, clinical Node status; CEA, carcinoembryonic antigen; GOLPH3, Golgi phosphoprotein 3.

The relationship between GOLPH3 and mTOR expression {#s2_4}
---------------------------------------------------

In this study, mTOR was also highly expressed in rectal cancer tissues, and 81 cases with high expression (81/148, 54.73%) were obtained, which was consistent with high GOLPH3 expression. There were 53 cases with high mTOR expression among the 77 patients showing high GOLPH3 expression; meanwhile, 43 cases with low mTOR expression were found among the 71 cases with low GOLPH3 expression. Then, the correlation between the two genes was tested by correlation analysis (*r* = 0.745, *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}).

![The expression of GOLPH3(G) and mTOR (T) were highly consistent in LARC cases\
(**A**) Immunohistochemical staining for GOLPH3 and mTOR in rectal cancer cells cytoplasm, magnification is 400×, a, b, c were three typical cases of high, medium and low expression. (**B**) mTOR was also highly expressed in rectal cancer tissues, and 81 cases with high expression (81/148, 54.73%). There were 53 cases with high mTOR expression among the 77 patients showing high GOLPH3 expression, and correlation analysis was done(*r* = 0.745, *P* \< 0.001). The color represented the number of each gene expressed respectively.](oncotarget-07-68328-g002){#F2}

Association between GOLPH3 and 5 year-DFS and OS {#s2_5}
------------------------------------------------

Single factor survival analysis indicated that lymphatic metastasis status, tumor invasion depth, and GOLPH3 expression were associated with 5 year-DFS and OS (Table [4](#T4){ref-type="table"}). Among the 148 LARC patients receiving nCRT, 5 year-DFS and OS in patients with high GOLPH3 expression were reduced compared with values obtained in the low expression group (*P* = 0.036 and 0.023, respectively) (Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). Multiple-factor analysis indicated that pN and pT were important prognosis factors for rectal cancer, as well as GOLPH3 expression. The prognosis of patients with high GOLPH3 expression was poorer compared with the low expression group. Indeed, GOLPH3 was shown to be an independent prognosis indicator for 5 year-DFS (HR = 2.624; 95% CI 1.235--6.541, *P* = 0.009) and OS (HR = 2.354; 95% CI 1.237--6.152, *P* = 0.039) in rectal cancer (Table [5](#T5){ref-type="table"}).

###### Univariate analysis between clinicopathological parameters and survival in patients with LARC

  Parameters                 Cases   5-year DFS, %   *P* value   5-year OS, %   *P* value
  -------------------------- ------- --------------- ----------- -------------- -----------
  Age(years)                                                                    
   \< 65                     67      65.3            0.611       73.2           0.536
   ≥ 65                      81      61.2                        70.9           
  Sex                                                                           
   Male                      89      66.2            0.632       78.7           0.412
   Female                    59      61.8                        66.8           
  Distance from anal verge                                                      
   \< 6 cm                   57      61.1            0.395       71.5           0.712
   ≥ 6 cm                    91      64.3                        72.3           
  Histology                                                                     
   Differentiated            82      65.8            0.503       77.8           0.438
   Undifferentiated          66      61.4                        72.1           
  CEA(ng/ml)                                                                    
   \< 3.4                    70      62.3            0.342       63.5           0.312
   ≥ 3.4                     78      58.1                        57.6           
  Pathological tumor stage                                                      
   pT0-2                     62      69.2            0.039       81.8           0.041
   pT3-4                     86      57.1                        60.2           
  Pathological node stage                                                       
   pN0                       88      75.6            0.031       79.2           0.029
   pN+                       60      56.1                        57.3           
  GOLPH3                                                                        
   Low                       71      69.0            0.036       70.4           0.023
   High                      77      51.9                        51.7           

Abbreviations: LARC, locally advanced rectal cancer; DFS, Disease free survival; OS, Overall survival; CEA, carcinoembryonic antigen; GOLPH3, Golgi phosphoprotein 3.

![Kaplan-Meier estimates of disease-free survival (DFS) and overall survival (OS) rates in relation to GOLPH3 status\
(**A**) GOLPH3 high expression in rectal cancers correlate with a shorter DFS curve (*P* = 0.036). (**B**) GOLPH3 high expression in rectal cancers correlate with a shorter OS curve (*P* = 0.023).](oncotarget-07-68328-g003){#F3}

###### Multivariate analysis of survival in LARC

  Parameters   Hazard ratio   95% Confidence interval   *P* value
  ------------ -------------- ------------------------- -----------
  5-year DFS                                            
   pT          2.311          1.230--5.124              0.023
   pN          2.589          1.574--4.935              0.015
   GOLPH3      2.624          1.235--6.541              0.009
  5-year OS                                             
   pT          2.435          0.967--5.952              0.066
   pN          2.635          0.358--6.891              0.052
   GOLPH3      2.354          1.237--6.152              0.039

Abbreviations: LARC, locally advanced rectal cancer; DFS, Disease free survival; OS, Overall survival; pT, pathological tumor stage; pN, pathological node stage; GOLPH3, Golgi phosphoprotein 3.

DISCUSSION {#s3}
==========

This is the first study to assess the associations of the new oncogene-GOLPH3 and nCRT in rectal cancer. The study confirmed the high expression of GOLPH3 in LARC, and revealed that GOLPH3 is an independent predictive factor for efficacy of nCRT. The underlying mechanism related with mTOR was also demonstrated.

In the study, we demonstrated that 77 of the 148 cases (52.03%) had high expression, which was higher than the rate obtained for normal tissue specimens (11/87, 12.64%; *P* \< 0.001). Scott et al. demonstrated that GOLPH3 was highly expressed in lung, ovarian, breast, and prostate cancers, as well as and melanoma, in 2009 \[[@R11]\]. Further studies indicated that GOLPH3 was highly expressed in malignant tumors, including breast cancer (expression rate, 51.6%), renal cancer (53.23%), pancreatic cancer (72.5%), and non-small cell lung cancer (71.7%), and closely related to clinical staging of tumor, also being a factor predicting poor prognosis \[[@R14]--[@R17]\]. Guo et al. \[[@R13]\] and Wang et al. \[[@R18]\] showed that GOLPH3 was highly expressed in colorectal cancer (53.2% and 43.1%, respectively), i.e. significantly higher than normal tissue rates (24.2% and 13.3%), in agreement with the current findings. Besides, Among the 77 patients with high GOLPH3 expression, 31 and 19 had local relapse and distant metastasis, respectively. The resulting rates were 2.58 and 2.71 fold those of the low expression group, with higher malignancy degree in the high expression group, corroborating findings by Guo et al. \[[@R13]\] and Wang et al. \[[@R18]\].

The reasons for therapy failure in rectal cancer include local relapse and distant metastasis. Interestingly, nCRT and TME surgery greatly decrease rectal cancer relapse \[[@R19], [@R20]\]. Total mesorectum excision is graded and qualified by the pathologist, and is a strong predictor of several outcomes. The results of Maslekar et al. confirmed that grade of mesorectun independently influenced both local and overall recurrences \[[@R21]\]. Meanwhile, Leite et al. revealed that the mesorectal score was an independent factor for local recurrence and disease-free survival \[[@R22]\]. Furthermore, Lino-Silva et al. used a two-grade system to determine the prognostic value of the mesorectum quality, and results suggested that inadequate mesorectum was correlated with R1/R2 resections, positive margins, and decrease survival, so the two-grade system (adequate, inadequate) was proposed \[[@R23]\]. Because of the adverse outcome of inadequate mesorectum patients, our study excluded this part.

However, sensitivity to nCRT of rectal cancer varies. Many factors affect the sensitivity of rectal cancer to nCRT, including tumor invasion depth, lymph node metastasis status and serum CEA level \[[@R24]\], in line with the current findings. However, identifying predictive gene markers of nCRT sensitivity not only predicts nCRT effects conveniently and efficiently, but also provides possible target genes for increasing nCRT sensitivity. Therefore, we assessed the associations of the new oncogene GOLPH3 and nCRT in LARC for the first time. In this study, single-factor analysis demonstrated that 44 of the 71 cases with low expression had tumor down-staging (*P* = 0.020), and 41 patients showed TRG3--4 after nCRT (*P* = 0.009). Multi-factor analysis showed that GOLPH3 was an independent predictive factor for TRG (OR = 3.952; CI 1.655--10.327, *P* = 0.026) and tumor down-staging (OR = 2.951; CI 1.523--11.324, *P* = 0.021) (Tables [2, 3](#T2){ref-type="table"}), suggesting GOLPH3 could reliably and independently predict sensitivity to nCRT in rectal cancer.

As carcinogenic mechanism, Scott et al. reported that GOLPH3 could activate the mTOR pathway \[[@R11]\], and Buschamn et al. found it could activate DNA-dependent protein kinase (DNA-PK), leading to DNA damage \[[@R10]\]. The yeast mTOR isomer (TOR) activates the Vps35 subunit of the retromer transport complex and regulates endocytosis. It was found that GOLPH3 could also activate Vps35 to increase mTOR activity. Furthermore, it improves various exogenous signals, and regulates the growth, proliferation and survival of cells \[[@R11], [@R25], [@R26]\]. Phosphorylation activation of the downstream protein p70 ribosomal S6 kinase (S6K) in the mTOR signaling pathway is closely related with copy number in the 5p13 fragment \[[@R6], [@R11], [@R27]\], suggesting GOLPH3 involvement in the tumor is related to the mTOR activity. Because GOLPH3 activates mTORC1 and mTORC2 pathways simultaneously \[[@R6], [@R11], [@R28]\], it could be deduced that if GOLPH3 expression is inhibited, mTOR down-stream signal pathways would be effectively decreased. Therefore, GOLPH3 could be used as an efficient target for tumor therapy. Besides, Scott et al. demonstrated that GOLPH3 could increase sensitivity to rapamycin \[[@R11]\]. In this study, GOLPH3 expression was found closely related to mTOR levels (*r* = 0.745), as shown by Figure [2](#F2){ref-type="fig"}. Whether the mTOR pathway is targeted by GOLPH3, with its inhibition reversing resistance to radiotherapy in rectal cancer needs to be addressed in future studies.

Single and multiple-factor analyses indicated that GOLPH3 was an independent prognosis factor for rectal cancer as listed in Tables [4, 5](#T4){ref-type="table"}. Indeed, the patients with high expression had poor prognosis, with 5 year-survival rates lower compared with the low group (51.7% vs. 70.4%) (Figure [3](#F3){ref-type="fig"}). Guo et al. found a 5 year-survival rate of 48.6% in patients with high GOLPH3 expression, for 69.4% in the low group \[[@R13]\], corroborating our findings. However, Wang et al. showed that DFS and OS of patients with colorectal cancer under 5-Fu adjuvant chemotherapy were improved in patients with high GOLPH3 expression \[[@R18]\]. The authors showed that GOLPH3 overexpression promoted the apoptotic effect of 5-Fu and increased sensitivity to 5-Fu, which resulted in increased survival. It is the mechanism underlying GOLPH3 effect on adjuvant/neoadjuvant chemotherapy that likely the primary cause for the difference between these results.

However, some inherent limitations of this study might lead to biased results. First, the current study was a retrospective study and the number of patients in our study was limited. Second, whether a biopsy is representative of the whole tumor need to be investigated because of tumor heterogeneity.

In conclusion, this study demonstrated that GOLPH3 was highly expressed in rectal cancer, and could predict sensitivity to nCRT in LARC; effect was better in patients with low expression. In addition, GOLPH3 expression was closely related to mTOR expression, indicating that it might act through the mTOR pathway. Finally, GOLPH3 was shown to be an independent prognosis factor for rectal cancer. However, due to the limitations of the current study, these findings should be confirmed by further well-designed experiments.

MATERIALS AND METHODS {#s4}
=====================

Patients and clinical assessment {#s4_1}
--------------------------------

Clinical and pathological characteristics of 163 cases with rectal cancer between January 2008 and December 2010 were retrospectively analyzed. Biopsy tissues were obtained by proctoscopy from the patients before therapy to confirm the pathological diagnosis of adenocarcinoma within 15 cm from the anal verge. Physical examination, CEA, routine blood test, chest enhancement CT, as well as abdomen and pelvic cavity enhancement CT were performed before therapy. Then, the patients were staged according to the AJCC criteria (Edition 7) \[[@R29]\]. Seven patients with distant metastasis and 5 others declining surgery after nCRT were excluded, as well as 3 cases who had insufficient tumor tissue samples. A total of 148 patients with rectal cancer in T3-T4/N+ stage receiving nCRT were included. They all had consistent basic characteristics, and provided signed informed consent. The study was approved by the Ethics Committee of Shandong Cancer Hospital.

Multimodal treatment {#s4_2}
--------------------

All the rectal cancer cases received nCRT, followed by surgical treatment (TME). Specifically, whole pelvic radiotherapy was performed with DT = 50.4Gy/28 times (four fields of irradiation or 3D conformal radiotherapy). The concurrent chemotherapy included 5-Fu (5-fluorouracil) continuously pumped or capecitabine in combination with oxaliplatin. TME was performed at 4∼6 weeks after nCRT.

Pathological assessment {#s4_3}
-----------------------

Two pathologists blinded to clinical information analyzed the postoperative pathological results, respectively. Preoperative biopsy tissues and postoperative pathological tissues were staged according to the AJCC staging criteria to assess the tumor down-staging effect of nCRT. Furthermore, sensitivity to nCRT of the tumor was assessed according to Dworak et al. \[[@R30]\]. The standards were as follows: TRG0, no regression; TRG1, tumor-based with significant fibrosis and/or vasculopathy; TRG2, fibrosis change-based with very few tumor cells or tissues (easily observed); TRG3, very few tumor cells in fibrotic tissues (easily observed by microscopy); TRG4, no tumor cells in fibrotic tissues (complete regression). TRG3 and 4 were defined as a good response, while TRG 0, 1 and 2 reflected a poor response. TRG 4 represented pCR.

Immunohistochemical analysis of GOLPH3 and mTOR {#s4_4}
-----------------------------------------------

A total of 148 biopsy tumor tissue samples before nCRT therapy were collected. The paraffin embedded specimens were sliced in 5 μm thickness, and GOLPH3 and mTOR expression levels were assessed by immunohistochemistry. Tissue sections were dewaxed by xylene, and hydrated by a graded ethanol series and distilled water. After antigen retrieval, normal rabbit serum was added (ZSGB-Bio, China) for blocking at room temperature for 20 min. Then, rabbit anti GOLPH3 and mTOR antibodies (Abcam, Cambridge, UK) at 1:200 were used to stain the samples for 1 h at room temperature. Goat anti-rabbit secondary antibodies (ZSGB-Bio) were added for 15 min at 37°C. Signals were revealed by 3,3-DAB, and hematoxylin was used for counterstaining. Finally, the slices were dehydrated by a graded ethanol series and xylene, mounted and examined by microscopy.

Two pathologists assessed the results according to the GOLPH3 scoring standard, to determine the rate of GOLPH3 positive cells and staining intensity as follows: 0, no positive cells; 1, 1∼10% positive tumor cells; 2, 11∼35% positive tumor cells; 3, 36∼70% positive tumor cells; 4, \> 70% positive tumor cells. Staining intensity was scored as follows: 0, no staining; 1, weak positive (slight yellow); 2, medium staining (claybank); 3, strong positive (sepia) \[[@R31]\].

Staining index for GOLPH3 expression was calculated by the two scoring systems, yielding possible scores of 0, 1, 2, 3, 4, 6, 9, and 12. Scores higher than 6 were considered high expression; those lower than 4 represented low expression \[[@R31]\]. To assess the relationship between mTOR and GOLPH3 levels, mTOR expression was assessed in a similar fashion.

Follow-up {#s4_5}
---------

The enrolled patients were followed-up strictly, once every 3 months in the first 2 years, and every 6 months in the following years. Median follow-up time was 58 months. Follow-up parameters included physical examination, serum CEA level, peripheral blood count, chest X-ray, as well as abdomen and pelvic cavity enhancement CT or MRI. Colonoscopy was performed once yearly.

Statistical analyses {#s4_6}
--------------------

For all the statistical analyses, spss 17.0 (SPSS Inc., Chicago, IL, USA) was used. The association of GOLPH3 status with clinicopathologic parameters (gender, age, differentiation, distance from anal verge, clinical tumor/node status, recurrence and distant metastasis) was assessed using the χ^2^-test. The Chi-squared test was also performed to assess the association between pathologic factors including GOLPH3 expression and tumor response. A multivariate stepwise logistic regression analysis was performed in order to determine the independent prediction of all variables that were significant in the univariate analysis. The associations between GOLPH3 and mTOR protein expression was analyzed by Chi-square test and correlation analysis. Overall survival (OS) was calculated from the initiation date of treatment to death from any causes or censored date of last contact for surviving patients. Disease free survival (DFS) was calculated from the initiation date of treatment to the date of any evidence of local or systemic cancer recurrence. The impact of the GOLPH3 status on OS and DFS was assessed by Kaplan-Meier method for the univariate survival analysis and Cox proportional hazards model for multivariate survival analysis. *P*-values \< 0.05 or 95% were considered statistically significant differences.
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